Olfactory and gustatory disorders in COVID-19

Research output: Contribution to journalReview articleContributedpeer-review

Contributors

Abstract

Loss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.

Details

Original languageEnglish
Pages (from-to)243-250
Number of pages8
Journal Allergo journal international : interdisciplinary journal of allergy, clinical immunology and environmental medicine
Volume31 (2022)
Issue number7
Early online date20 Jun 2022
Publication statusPublished - Oct 2022
Peer-reviewedYes

External IDs

PubMedCentral PMC9208356
Scopus 85132168953
Mendeley e5aaa586-d2cc-3270-8328-d4db12a0c330
unpaywall 10.1007/s40629-022-00216-7
ORCID /0000-0001-9713-0183/work/146645219

Keywords

ASJC Scopus subject areas

Keywords

  • Anosmia, COVID-19, Olfactory dysfunction, Postviral anosmia, Rhinitis

Library keywords